Lates News

According to the AI Flash News of Every Economic, Open Source Securities released a research report on April 22, giving Hisheng Pharmaceutical (920656.SH) a "buy" rating. The rating reasons mainly include: 1) A year-on-year increase of 36.86% in net profit attributable to the parent company in 2025, and a year-on-year increase of 51.52% in net profit attributable to the parent company in Q1 of 2026; 2) The improvement of the aquaculture industry promotes the simultaneous increase in the volume and price of APIs, and the acceleration of diversified product layout; 3) The steady growth of the API and veterinary drug industries, and the continuous increase in market capacity. (Daily Economic News)